Industry
Biotechnology
IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 14, 2024 | 11:58 am
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 6:52 pm
Portfolio Pulse from Benzinga Newsdesk
August 13, 2024 | 11:10 am
Portfolio Pulse from Benzinga Newsdesk
May 15, 2024 | 3:39 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 4:05 pm
Portfolio Pulse from Benzinga Insights
March 06, 2024 | 9:31 pm
Portfolio Pulse from Benzinga Newsdesk
March 06, 2024 | 1:21 pm
Portfolio Pulse from Happy Mohamed
March 05, 2024 | 9:43 pm
Portfolio Pulse from Avi Kapoor
January 22, 2024 | 12:34 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.